Myrexis

Myrexis, Inc. is in the process of evaluating strategic alternatives, including focusing on identifying, evaluating, and making financial investments in life sciences assets. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The company went IPO on 2009-06-12. The firm was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The firm determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The firm operates in pharmaceutical development and related research activities. The Company’s revenues were derived from research performed in the United States and, all of the Company’s long-lived assets are located in the United States.